Crohn'
Conditions
Interventions
At the time of resumption of food, patients recerve 9mg/day budesonide orally for 3 weeks, followed by 6mg/day for 1 week.
Sponsors
Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology
Japan Community Health care Organizationi Osaka Hospital, Gastroenterology and Hepatology National Hospital Organization Osaka National Hospital, Gastroenterology and Hepatology Osaka Rosai Hospital , Gastroenterology and Hepatology Kansai Rosai Hospital, Gastroenterology and Hepatology Itami City Hospital, Gastroenterology and Hepatology Hyogo Prefectural Nishinomiya Hospital, Gastroenterology and Hepatology Nishinomiya Municipal central hospital, Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Mild to moderate active Crohn's disease patients with written consent at Osaka University Hospital and affiliated hospitals, who have intestinal stenosis and are scheduled or recieved endoscopic balloon dilation (EBD), are included.
Exclusion criteria
Exclusion criteria: Patients with more than 5 centimeters long stenosis Patients with internal or external fistula Patients with active infection, including abscess Patients with oral treatment of antithrombotic drugs or low platelet that counts less than 50000 per microlitter Patients with cancer Patients under 20 years old Patients with severy bad general condition Patients who are administered steroids within 4 weeks Patients who are judged inapropriate by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety within 12 weeks after EBD | — |
Secondary
| Measure | Time frame |
|---|---|
| safety within 52 weeks after EBD rate of non-intestinal resection, non-reEBD and non-hospitalization rate of non-restenosis at 52 weeks after EBD | — |
Countries
Japan
Contacts
Public ContactShinichiro Shinzaki
Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed